Trailblazing Science. Industry-leading Multispecifics.
“We focus on known cancer targets and bispecific architectures, building on existing understanding in the pursuit of better molecules with greater patient benefit.”
Chris Mehlin, PhD, Co-founder and Chief Scientific Officer
Pushing Beyond What is Known
Based on fundamental biology and current knowledge, we are developing next-generation immune-targeting therapeutics with increased specificity, reduced toxicity, and unparalleled efficacy.
Pushing Beyond What Is Known
Based on fundamental biology and current knowledge, we are developing next-generation immune-targeting therapeutics with increased specificity, reduced toxicity, and unparalleled efficacy.
Rigorous Science and Passion to Deliver for Patients
Respect and care for each other is the energy that fuels us. We are a team of experienced professionals united by our common mission and determination to create therapeutics that help cancer patients thrive.
Experience and Drive
We dig deeper and explore further in our unrelenting quest to build first-in-class antibodies.
Experience and Drive
We dig deeper and explore further in our unrelenting quest to build first-in-class antibodies.